First-line therapies for advanced HCC show similar results

Key clinical point: No single first-line treatment for advanced hepatocellular carcinoma demonstrated superior outcomes across all measures, therefore treatment should be based on individual goals.

Major finding: Lenvatinib ranked highest for overall response rate for patients with advanced/unresectable HCC, followed by atezolizumab plus bevacizumab and nivolumab. For progression-free survival, the top-ranked treatments was atezolizumab + bevacizumab, followed by lenvatinib.

Study details: The data come from a meta-analysis of 27 randomized, controlled trials of first-line therapies for hepatocellular carcinoma. The treatments compared in the studies were Treatments compared were atezolizumab plus bevacizumab, brivanib, donafenib, dovitinib, FOLFOX4, lenvatinib, linifanib, nintedanib, nivolumab, sorafenib, sunitinib, vandetanib, 11 sorafenib combination therapies, and 3 other combination therapies. 

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Han Y et al. World J. Gastroenterol. 2021 May 21. doi: 10.3748/wjg.v27.i19.2415.

Key clinical point: No single first-line treatment for advanced hepatocellular carcinoma demonstrated superior outcomes across all measures, therefore treatment should be based on individual goals.

Major finding: Lenvatinib ranked highest for overall response rate for patients with advanced/unresectable HCC, followed by atezolizumab plus bevacizumab and nivolumab. For progression-free survival, the top-ranked treatments was atezolizumab + bevacizumab, followed by lenvatinib.

Study details: The data come from a meta-analysis of 27 randomized, controlled trials of first-line therapies for hepatocellular carcinoma. The treatments compared in the studies were Treatments compared were atezolizumab plus bevacizumab, brivanib, donafenib, dovitinib, FOLFOX4, lenvatinib, linifanib, nintedanib, nivolumab, sorafenib, sunitinib, vandetanib, 11 sorafenib combination therapies, and 3 other combination therapies. 

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Han Y et al. World J. Gastroenterol. 2021 May 21. doi: 10.3748/wjg.v27.i19.2415.

Key clinical point: No single first-line treatment for advanced hepatocellular carcinoma demonstrated superior outcomes across all measures, therefore treatment should be based on individual goals.

Major finding: Lenvatinib ranked highest for overall response rate for patients with advanced/unresectable HCC, followed by atezolizumab plus bevacizumab and nivolumab. For progression-free survival, the top-ranked treatments was atezolizumab + bevacizumab, followed by lenvatinib.

Study details: The data come from a meta-analysis of 27 randomized, controlled trials of first-line therapies for hepatocellular carcinoma. The treatments compared in the studies were Treatments compared were atezolizumab plus bevacizumab, brivanib, donafenib, dovitinib, FOLFOX4, lenvatinib, linifanib, nintedanib, nivolumab, sorafenib, sunitinib, vandetanib, 11 sorafenib combination therapies, and 3 other combination therapies. 

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Han Y et al. World J. Gastroenterol. 2021 May 21. doi: 10.3748/wjg.v27.i19.2415.